A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform “fungerps”, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and most common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals and was approved by the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 21M | 21M | - | - | - | - |
| Net Income | -8.6M | -8.6M | -21M | 67M | -63M | -33M |
| EPS | $-0.17 | $-0.17 | $-0.44 | $1.39 | $-1.47 | $-1.25 |
| Free Cash Flow | -5.3M | -5.3M | -24M | 60M | -80M | -55M |
| ROIC | -45.2% | -17.4% | -38.7% | 99.4% | -77.2% | -46.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.20 | 0.65 | 0.76 | 10.64 | 0.70 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -16M | -16M | -37M | 73M | -86M | -61M |
| Operating Margin | -78.0% | -78.0% | - | - | - | - |
| ROE | -17.4% | -16.5% | -38.7% | 91.9% | -1942.7% | -79.7% |
| Shares Outstanding | 51M | 51M | 48M | 48M | 43M | 26M |
SCYNEXIS INC passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -13.7%.
SCYNEXIS INC (SCYX) has a 5-year average return on invested capital (ROIC) of -16.2%. This is below average and may indicate limited pricing power.
SCYNEXIS INC (SCYX) has a market capitalization of $52M. It is classified as a small-cap stock.
SCYNEXIS INC (SCYX) does not currently pay a regular dividend.
SCYNEXIS INC (SCYX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
SCYNEXIS INC (SCYX) reported annual revenue of $21 million in its most recent fiscal year, based on SEC EDGAR filings.
SCYNEXIS INC (SCYX) has a net profit margin of -41.8%. The company is currently unprofitable.
SCYNEXIS INC (SCYX) generated $-5 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SCYNEXIS INC (SCYX) has a debt-to-equity ratio of 0.20. This indicates a conservatively financed balance sheet.
SCYNEXIS INC (SCYX) reported earnings per share (EPS) of $-0.17 in its most recent fiscal year.
SCYNEXIS INC (SCYX) has a return on equity (ROE) of -16.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 13 years of financial data for SCYNEXIS INC (SCYX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SCYNEXIS INC (SCYX) has a book value per share of $0.98, based on its most recent annual SEC filing.